Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Neurotoxicity Research|July 2, 2003
Axonal degeneration and progressive neurologic disability in multiple sclerosisCarl Bjartmar, Bruce D TrappAnnals of Neurology|January 10, 2002
N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerveCarl Bjartmar, Jan Battistuta, Nobuo Terada, et al.BMC Neurology|April 7, 2018
Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating ScaleAnna Członkowska, Tomasz Litwin, Karolina Dzieżyc, et al.Glia|February 16, 2005
Beta IV tubulin is selectively expressed by oligodendrocytes in the central nervous systemNobuo Terada, Grahame J Kidd, Mike Kinter, et al.Journal of Neuropathology and Experimental Neurology|February 7, 2002
Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosisJerome R Wujek, Carl Bjartmar, Edward Richer, et al.Glia|November 7, 2002
The tetraspanin protein, CD9, is expressed by progenitor cells committed to oligodendrogenesis and is linked to beta1 integrin, CD81, and Tspan-2Nobuo Terada, Karen Baracskay, Mike Kinter, et al.The Lancet. Gastroenterology & Hepatology|October 10, 2017
Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 studyKarl Heinz Weiss, Frederick K Askari, Anna Czlonkowska, et al.Neuromuscular Disorders : NMD|January 26, 2015
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe diseaseLaura E Case, Carl Bjartmar, Claire Morgan, et al.Molecular Genetics and Metabolism|July 31, 2016
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY StudyAns van der Ploeg, Pierre G Carlier, Robert-Yves Carlier, et al.Pageof 1